Designer Opioid Session (link to download)

DESIGNER OPIOID SPECIAL SESSION

NEAFS 2017

DATE: NOV 10, 2017

TIME: 9:00 AM – 12:15 PM

In recent years the use of novel psychoactive substances has skyrocketed. What began with heroin and fentanyl has swiftly progressed into fentanyl analogues and other designer opioids. From an analytical perspective there are several distinct challenges especially in regard to detection and determining the appropriate target substances in biologicals. Interpretation is complicated since complete data about potency, metabolism, duration of action and other pharmacokinetic parameters are not available. The purpose of this workshop is to provide a historical perspective on the designer opioid crisis, detail laboratory responsibilities including method validation and safe handling practices of exhibits, review the pharmacology and pharmacokinetic parameters of these substances with analyte-specific examples, and supplement the information with case examples as they pertain to the interpretation of human performance impairment and postmortem cases.

Schedule

9:00-9:30 AM (Speaker: L. Labay)

A Historical Perspective: How did we get here?

9:30-10:15 AM (Speaker: M. Lamb)

Everything Laboratory: Method Development and Validation, Analysis and Safety Practices

10:15-10:30 AM

15 min break

10:30-11:15 AM (Speaker: S. Gagen)

Pharmacology and Pharmacokinetics: Facts and Suppositions with Analyte Specific Examples

11:15-12:00 PM (Speaker: L. Labay)

Interpretation of DUID and PM cases with Case Specific Examples

12:00-12:15 PM

Questions and Concluding Remarks

SPEAKERS:

 

Sara C. Gagen, M.S.

Analyst III

NMS Labs, Willow Grove, PA

Michael E. Lamb, M.S.

Analyst III

NMS Labs, Willow Grove, PA

Laura M. Labay, PhD, F-ABFT, DABCC-TC

Forensic Toxicologist; Director of Toxicological Services

NMS Labs, Willow Grove, PA